This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaplan, S. A. Articles by Cohen, P. Search for Related Content PubMed PubMed Citation Articles by Kaplan, S. A. Articles by Cohen, P. Related Collections Neuroendocrinology and Pituitary Metabolism

REVIEW: The Somatomedin Hypothesis 2007: 50 Years Later

David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095

Address all correspondence and requests for reprints to: Solomon A. Kaplan, M.D., Professor Emeritus, Department of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095-1752. E-mail: skaplan{at}mednet.ucla.edu.

Context: The somatomedin/IGF hypothesis was based on the observation that GH was inactive when added to an in vitro incubation system but required a GH-dependent substance in the circulation to mediate its activity. Newer experimental evidence has led to several modifications of the hypothesis, but none of the proposed modifications accounts for all of the integrated actions of GH and IGF-I. In this paper, we propose an augmentative/counteractive modification of the existing hypothesis that takes into account all the actions of the GH-IGF system.

Evidence Acquisition: The modification is based on experimental evidence published since the hypothesis was originally developed.

Evidence Synthesis: The modification is based on an integration of the results of published experimental evidence regarding the actions of GH and the IGF complex.

Conclusion: We propose a new augmentative/counteractive modification of the hypothesis that the actions of the GH-IGF system provide a distinct evolutionary advantage to the organism by augmenting the anabolic actions of GH while countering its potentially deleterious effects of hyperglycemia and depletion of lipid stores.

This article has been cited by other articles:

				E. Stratikopoulos, M. Szabolcs, I. Dragatsis, A. Klinakis, and A. Efstratiadis The hormonal action of IGF1 in postnatal mouse growth PNAS, December 9, 2008; 105(49): 19378 - 19383. [Abstract] [Full Text] [PDF]

				J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials Mol. Cancer Ther., September 1, 2008; 7(9): 2575 - 2588. [Abstract] [Full Text] [PDF]

				A. C.-M. Chang, J. Hook, F. A. Lemckert, M. M. McDonald, M.-A. T. Nguyen, E. C. Hardeman, D. G. Little, P. W. Gunning, and R. R. Reddel The Murine Stanniocalcin 2 Gene Is a Negative Regulator of Postnatal Growth Endocrinology, May 1, 2008; 149(5): 2403 - 2410. [Abstract] [Full Text] [PDF]